Valeant Pharmaceuticals International, Inc. (VRX) Closed at $12.66

John Paulson

14,674,829 shares of the stock traded hands. Gramercy Funds Management LLC purchased a new position in Valeant Pharmaceuticals International during the third quarter valued at approximately $614,000. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $32.74. Conning owns 109,769 shares or 0.06% of their U.S. portfolio. OLD Mutual Customised Solutions Proprietary Ltd. boosted its position in Valeant Pharmaceuticals International by 357.7% in the first quarter. The Scepter Holdings Inc holds 500,000 shares with $7.26M value, down from 600,000 last quarter. Searle & CO. purchased a new stake in Valeant Pharmaceuticals International during the fourth quarter worth approximately $972,000. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company's stock worth $105,000 after buying an additional 1,500 shares during the period. 24,000 shares were bought by Herendeen Paul, worth $257,280. Alpha One also assigned press coverage about the specialty pharmaceutical company an impact score of 21 out of 100, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the next several days.

VRX is down 10% year-to-date, and the stock is staring up at its 150-day moving average, which capped a mid-May rally attempt. The company has market cap of $4.53 billion. Valeant Pharmaceuticals International also saw some unusual options trading activity on Friday. This is an increase of 215% compared to the average daily volume of 11,124 put options. PEG ratio for Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is 0.00. Valeant Pharmaceuticals International had a positive return on equity of 58.02% and a negative net margin of 14.96%. The firm had revenue of $2.11 billion for the quarter, compared to analyst estimates of $2.17 billion. During the same period a year ago, the firm posted ($1.08) EPS. Valeant Pharmaceuticals International's quarterly revenue was down 11.1% compared to the same quarter a year ago. Valeant Pharmaceuticals International had 34 analyst reports since October 20, 2015 according to SRatingsIntel.

WARNING: This piece of content was originally published by BBNS and is the sole property of of BBNS. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and worldwide copyright and trademark law.

Valeant shares were up 45 cents, or 3.55%, to $13.10 in premarket trading Monday. Deutsche Bank AG dropped their price objective on Valeant Pharmaceuticals International from $20.00 to $19.00 and set a "hold" rating for the company in a report on Tuesday, March 7th. The financial firm set Overweight rating on the stock. The firm has "Neutral" rating given on Monday, November 2 by Goldman Sachs. Royal Bank Of Canada reduced their target price on shares of Valeant Pharmaceuticals International to $21.00 in a report on Wednesday, March 1st. The SEC filing shows that DE SCHUTTER RICHARD U performed a purchase of 10,000 shares. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) earned "Sector Perform" rating by RBC Capital Markets on Monday, January 16. It is meant to chart the current and historical strength or weakness of a stock or market based on the closing prices of a recent trading period. Us Commercial Bank De reported 492 shares.

In the transaction dated March 14, 2017, the great number of shares acquired came courtesy the; ValueAct Capital Master Fund, added a total of 3,000,000 shares at an average price of $10.82, amounting to approximately $32,460,000. The 200 SMA is considered so critically important a trend indicator that the event of the 50-day SMA crossing to the downside of the 200-day SMA is referred to as a death cross, signaling a serious bear market in a stock, index or other investment.

Key Group Holdings Cayman Ltd increased Williams Clayton Energy Inc (CWEI) stake by 16.1% reported in 2016Q4 SEC filing. He is now a director at insurer American International Group Inc AIG.N , which recently removed its CEO.

Valeant Pharmaceuticals International, a pharmaceutical and medical device company.



Other news